01 / DESIGN
What was studied?
The study randomized 50 adults receiving HIV therapy who had abdominal fat accumulation. It compared tesamorelin with placebo over six months.
02 / FINDINGS
What did the researchers report?
Visceral fat decreased and liver fat showed a modest reduction with tesamorelin relative to placebo. Early fasting-glucose changes were also observed, underlining the value of safety monitoring.
03 / LIMITS
How should it be interpreted?
The authors described the study as preliminary. Its size, duration and HIV-specific population limit broader conclusions, and changes in imaging measurements do not alone establish long-term health benefits.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.